Our efficacy findings are in line with previous reports on oral treatment with BRAF inhibitors in BRAF V600-mutated anaplastic and papillary thyroid cancer, in which efficacy of treatment was reported. The gene discussed is BRAF; the disease is thyroid gland papillary carcinoma.